1
|
Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2018; 2018:2426712. [PMID: 29682155 PMCID: PMC5851432 DOI: 10.1155/2018/2426712] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/24/2017] [Accepted: 11/06/2017] [Indexed: 12/31/2022]
Abstract
Altered cellular metabolism is considered a hallmark of cancer and is fast becoming an avenue for therapeutic intervention. Mitochondria have recently been viewed as an important cellular compartment that fuels the metabolic demands of cancer cells. Mitochondria are the major source of ATP and metabolites necessary to fulfill the bioenergetics and biosynthetic demands of cancer cells. Furthermore, mitochondria are central to cell death and the main source for generation of reactive oxygen species (ROS). Overall, the growing evidence now suggests that mitochondrial bioenergetics, biogenesis, ROS production, and adaptation to intrinsic oxidative stress are elevated in chronic lymphocytic leukemia (CLL). Hence, recent studies have shown that mitochondrial metabolism could be targeted for cancer therapy. This review focuses the recent advancements in targeting mitochondrial metabolism for the treatment of CLL.
Collapse
|
2
|
Janssens A, Roy N, Poppe B, Noens L, Philippé J, Speleman F, Offner F. High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature. Eur J Haematol 2012; 89:72-80. [DOI: 10.1111/j.1600-0609.2012.01790.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/08/2012] [Indexed: 12/01/2022]
Affiliation(s)
- Ann Janssens
- Department of Haematology; Ghent University Hospital; Ghent; Belgium
| | - Nadine Roy
- Center for Medical Genetics; Ghent University Hospital; Ghent; Belgium
| | - Bruce Poppe
- Center for Medical Genetics; Ghent University Hospital; Ghent; Belgium
| | - Lucien Noens
- Department of Haematology; Ghent University Hospital; Ghent; Belgium
| | - Jan Philippé
- Department of Clinical Biology, Microbiology, and Immunology; Ghent University Hospital; Ghent; Belgium
| | - Frank Speleman
- Center for Medical Genetics; Ghent University Hospital; Ghent; Belgium
| | - Fritz Offner
- Department of Haematology; Ghent University Hospital; Ghent; Belgium
| |
Collapse
|
3
|
Fegan CD, Davies FE. Karyotypic and molecular abnormalities in chronic lymphocytic leukaemia. Mol Pathol 2010; 49:M185-91. [PMID: 16696072 PMCID: PMC408056 DOI: 10.1136/mp.49.4.m185] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- C D Fegan
- Department of Haematology, Birmingham Heartlands Hospital and Solihull Trust, Bordesley Green East, Birmingham B9 5SS
| | | |
Collapse
|
4
|
Vitale B, Martinis M, Antica M, Kusić B, Rabatić S, Gagro A, Kusec R, Jaksić B. Prolegomenon for Chronic Lymphocytic Leukaemia. Scand J Immunol 2003; 58:588-600. [PMID: 14636414 DOI: 10.1111/j.1365-3083.2003.01331.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Chronic lymphocytic leukaemia (CLL) is a unique lymphoproliferative disorder that scarcely occurs under the age of 40; thereafter the incidence of CLL increases exponentially with age. CLL is characterized by progressive expansion of malignant CD5+ME+ B-cell clone accompanied by a myriad of cellular and humoral immune defects. Each of them might be linked to different clinically manifested complications such as increasing rate of infections, autoimmune disorders and disturbed immune surveillance against tumour cells. We assume that CLL occurs as a consequence of age-dependent, genetically related functional restrictions of the thymic microenvironment in supporting common lymphoid progenitor cells (CD5+ME+CD4-CD8-) to differentiate into mature T-cell and B-cell descendants. In conjunction with genetic abnormalities developing in B-cell progenitors, presumably expressing P glycoprotein (Pgp+), we postulate that developmentally altered T-cell descendants, along with quantitative imbalance among CD4+, their subsets and CD8+ lymphocytes in the peripheral blood, play an important additional role in facilitating the malignant B-cell clone emergence and in modulating the CLL clinical evolution. Namely, imbalance of any of T-cell-mediated cell interactive homeostatic mechanisms accompanied by imbalance in the production of various cytokines might in CLL influence leukaemic B-cell growth by deregulating inducer (c-myc and p53) and/or suppressor (bcl-2 and mutant p53) oncogenes responsible for the promotion or suppression of B-cell mitogenesis that may in turn further contribute to their impaired differentiation and/or differentiation arrest. In conclusion, CLL might be interpreted as a primary immunodeficiency syndrome developing in elderly population due to gradually evolving restriction of genetically controlled programs in the thymic microenvironment responsible for irregular maturation of common lymphoid progenitor cells that constitutively express CD5 antigen and ME receptor into T-cell and B-cell descendants.
Collapse
MESH Headings
- B-Lymphocytes/immunology
- Cell Communication
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/etiology
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Polymorphism, Genetic
- Prognosis
- T-Lymphocytes/immunology
- Thymus Gland/physiology
Collapse
Affiliation(s)
- B Vitale
- Department of Molecular Medicine, Merkur University Hospital, Zagreb, Croatia.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Barnabas N, Shurafa M, Van Dyke DL, Wolman SR, Clark D, Worsham MJ. Significance of p53 mutations in patients with chronic lymphocytic leukemia: a sequential study of 30 patients. Cancer 2001; 91:285-93. [PMID: 11180073 DOI: 10.1002/1097-0142(20010115)91:2<285::aid-cncr1000>3.0.co;2-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND In patients with B-cell chronic lymphocytic leukemia (CLL), considerable disease heterogeneity within clinical stages necessitates the search for relevant prognostic indicators, particularly those that may help to determine the need for early therapeutic intervention. In the current study, the authors investigated the role of p53 mutations and chromosomal abnormalities in 30 patients with CLL. METHODS Thirty patients were screened for p53 mutations. Half of the group had aggressive disease characterized by leucocytosis, lymph node enlargement, organomegaly, and shortened tumor doubling time. Because 95% of p53 mutations reside in "hot-spot" regions of exons 5-9 of the p53 gene, the authors sequenced these exons completely for mutation detection. RESULTS Sequence analysis identified p53 mutations in 14 of 30 patients that were distributed equally among patients with aggressive disease and nonaggressive disease. There were six mutations in exon 7, five mutations in exon 5, and one mutation each in exons 6 and 8. Five of 15 patients with clinically aggressive disease had mutations in exon 7. Only one patient with nonaggressive disease had an exon 7 mutation. Abnormal cytogenetics were present in 22 of 30 patients (73%). Most patients with the p53 mutation (13 of 14 patients; 93%) displayed abnormal cytogenetics. Twelve of 15 patients with aggressive disease and 9 of 15 patients with average disease exhibited abnormal karyotypes. CONCLUSIONS The presence of p53 mutations did not predict clinical behavior or disease outcome, although the frequency of mutations appears to be higher than reported previously. In this study, mutations of exon 7 (5 of 6 patients) occurred in patients with clinically aggressive disease. The significance of this observation warrants further examination.
Collapse
MESH Headings
- Exons/genetics
- Genes, p53/genetics
- Humans
- Karyotyping
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Mutation/genetics
- Polymorphism, Single-Stranded Conformational
- Sequence Analysis, DNA
Collapse
Affiliation(s)
- N Barnabas
- Department of Pathology, Henry Ford Health System, Detroit, Michigan 48202, USA
| | | | | | | | | | | |
Collapse
|
6
|
Nagata T, Mugishima H, Yoden A, Yoshikawa K, Oguni T, Yamashiro K, Yamamori S, Harada K. A case of monoclonal gammopathy associated with acute myelomonocytic leukemia with eosinophilia suggested to be the result of lineage infidelity. Am J Hematol 2000; 65:66-71. [PMID: 10936867 DOI: 10.1002/1096-8652(200009)65:1<66::aid-ajh12>3.0.co;2-t] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Acute myelomonocytic leukemia (AMMoL) accompanied by monoclonal gammopathy is a rare condition, and its pathogenesis and the cytogenetic mechanism of such leukemogenesis have not been determined in detail. A case of AMMoL with eosinophilia accompanied by immunoglobulin G kappa monoclonal gammopathy is described. Immunophenotypic studies of the peripheral blood and bone marrow mononuclear cells revealed no evidence of abnormally proliferating cells of B-lineage. DNA analyses of bone marrow mononuclear cells containing leukemic cells revealed rearrangement of the kappa-light chain (Igkappa) gene and c-myc and c-jun proto-oncogenes. The intensities of the rearranged bands for these genes on Southern blot analysis suggested the existence of a major population of leukemic cells with rearranged Igkappa gene and minor population(s) of leukemic cells with rearranged c-myc and/or c-jun proto-oncogene(s) in the patient's bone marrow and indicated the occurrence of genetic evolutionary changes in leukemic cells in this patient before starting chemotherapy. These results suggest that these leukemic cells are the most likely candidate for immunoglobulin G kappa monoclonal protein production, and structural abnormalities of c-myc and c-jun proto-oncogenes may have contributed to the evolution of leukemic cells in this patient.
Collapse
MESH Headings
- Blotting, Southern
- Bone Marrow Cells/chemistry
- Cell Division
- Child, Preschool
- DNA/analysis
- Eosinophilia/complications
- Gene Rearrangement
- Genes, fos
- Genes, jun
- Genes, myc
- Humans
- Immunoglobulin G
- Immunoglobulin kappa-Chains/genetics
- Immunophenotyping
- Leukemia, Myelomonocytic, Acute/complications
- Leukemia, Myelomonocytic, Acute/drug therapy
- Leukemia, Myelomonocytic, Acute/genetics
- Leukocytes, Mononuclear/chemistry
- Leukocytes, Mononuclear/immunology
- Male
- Paraproteinemias/complications
- Paraproteinemias/genetics
- Proto-Oncogene Mas
Collapse
Affiliation(s)
- T Nagata
- Department of Pediatrics, Nihon University, School of Medicine, Tokyo, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Pescarmona E, Pignoloni P, Santangelo C, Naso G, Realacci M, Cela O, Lavinia AM, Martelli M, Russo MA, Baroni CD. Expression of p53 and retinoblastoma gene in high-grade nodal peripheral T-cell lymphomas: immunohistochemical and molecular findings suggesting different pathogenetic pathways and possible clinical implications. J Pathol 1999; 188:400-6. [PMID: 10440751 DOI: 10.1002/(sici)1096-9896(199908)188:4<400::aid-path379>3.0.co;2-#] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The expression of p53 and the retinoblastoma gene has been investigated by immunohistochemical and molecular analysis in 45 cases of nodal peripheral T-cell lymphoma with high-grade histology. Most cases (73.3 per cent) were primary nodal lymphomas without any extra-nodal site involvement. Most of them (75.6 per cent) were histologically classified as pleomorphic, small, medium, and large cell type. Immunohistochemistry detected p53 in nine cases (20 per cent). In each of these cases, the polymerase chain reaction (PCR)/heteroduplex analysis did not show the presence of mutations, this finding being consistent with an alteration of the p53 functional pathway, in the presence of a wild-type protein. The retinoblastoma gene product was detected by immunohistochemistry in 35 cases (77.8 per cent) and not detected in ten cases (22.2 per cent). In the latter cases, the reverse transcription (RT)-PCR analysis showed the presence of a specific retinoblastoma gene transcript in six cases and was negative in the remaining four cases. The immunohistochemical and molecular findings seem to be consistent with abnormalities of retinoblastoma gene expression at either the transcriptional or the post-transcriptional level. Since all nine p53-positive cases by immunohistochemical analysis were also retinoblastoma gene product-positive, and all ten retinoblastoma gene product-negative cases were also p53-negative, two different and mutually exclusive pathways of possible pathogenetic significance may be suggested, the former involving abnormalities of the functional pathway of p53 in the absence of mutations and the latter abnormalities of retinoblastoma gene expression at the transcriptional and/or post-transcriptional level. Finally, the clinico-pathological correlations showed that p53 immunohistochemical expression is significantly associated with a poorer response to intensive chemotherapy.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor/metabolism
- Cell Division
- Female
- Gene Expression
- Genes, Retinoblastoma
- Genes, p53
- Humans
- Lymphoma, T-Cell, Peripheral/drug therapy
- Lymphoma, T-Cell, Peripheral/genetics
- Lymphoma, T-Cell, Peripheral/metabolism
- Male
- Middle Aged
- Neoplasm Proteins/metabolism
- Retinoblastoma Protein/metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Treatment Outcome
- Tumor Suppressor Protein p53/metabolism
Collapse
Affiliation(s)
- E Pescarmona
- II Cattedra di Anatomia ed Istologia Patologica, Dipartimento di Medicina Sperimentale e Patologia, Policlinico Umberto I, Rome, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Hogan WJ, Tefferi A, Borell TJ, Jenkins R, Li CY, Witzig TE. Prognostic relevance of monosomy at the 13q14 locus detected by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. CANCER GENETICS AND CYTOGENETICS 1999; 110:77-81. [PMID: 10214353 DOI: 10.1016/s0165-4608(98)00207-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Deletion of the chromosome band 13q14, which contains the putative deleted in B-cell malignancy (DBM) gene, and trisomy 12 have been demonstrated by fluorescence in situ hybridization (FISH) techniques in malignant B-cells from patients with B cell chronic lymphocytic leukemia (B-CLL). However, the prognostic relevance of 13q14 abnormalities as detected by FISH is unknown. We prospectively studied malignant blood cells from 54 consecutive, untreated B-CLL patients using FISH probes to the RB1 locus and DBM (markers D13S25 and D13S319) for band 13q14, as well as probes to chromosome 12. The cells from all cases were CD5+ CD20+, expressed clonally restricted surface immunoglobulin light chain, and had typical features for B-CLL on careful blood smear morphologic evaluation. Patients were followed for a mean of 3.9 years and treatment-free survival (TFS) was used in the prognostic factor analysis. Twenty-four (44%) patients were observed to have monosomy of the RB1 locus and 26 (48%) monosomy of D13S25 and D13S319. The 26 patients who had a deletion at at least one of these loci had a 48.4 month (mo) median TFS vs 31.1 mo for those without evidence of deletion at any 13q14 locus (p = 0.07). The seven patients found to have trisomy 12 had a median TFS of 6.9 mo vs 39.3 mo for those diploid for chromosome 12 (p < 0.01). When these seven patients with trisomy 12 were excluded from the analysis, patients who had a deletion at 13q14 tended to have a longer median TFS (50.1 vs 36.2 mos), but this was not statistically significant (p = 0.2). This study confirms the prevalence of 13q14 deletions in B-CLL and suggests that patients with this abnormality have a better TFS than those with trisomy 12.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Chromosomes, Human, Pair 12
- Chromosomes, Human, Pair 13
- Diploidy
- Female
- Humans
- In Situ Hybridization, Fluorescence
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Male
- Middle Aged
- Monosomy/genetics
- Predictive Value of Tests
- Prognosis
- Survival Rate
Collapse
Affiliation(s)
- W J Hogan
- Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | | | |
Collapse
|
9
|
Liu KZ, Schultz CP, Johnston JB, Lee K, Mantsch HH. Comparison of infrared spectra of CLL cells with their ex vivo sensitivity (MTT assay) to chlorambucil and cladribine. Leuk Res 1997; 21:1125-33. [PMID: 9444947 DOI: 10.1016/s0145-2126(97)00060-x] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The drug resistance of leukemic cells from 21 patients with chronic lymphocytic leukemia (CLL) to the alkylating agent chlorambucil (CLB) and the nucleoside analog cladribine or 2-chlorodeoxyadenosine (CdA) was investigated by infrared spectroscopy. Drug sensitivities, determined in vitro with the tetrazolium dye (MTT) assay, were correlated with the infrared spectra of the CLL cells, applying linear discriminant analysis (LDA). The 63 spectra (three from each of the 21 samples), obtained before drug exposure, were successfully partitioned into drug-sensitive and drug-resistant groups; the LDA-based ex vivo prediction of the sensitivity to CdA or CLB was 85.7% and 80.3%, respectively. Similar changes in the composition/structure of DNA were observed between the spectra of the drug-sensitive and drug-resistant CLL cells for both CdA and CLB. However, CdA-resistant CLL cells could also be differentiated from CdA-sensitive CLL cells by spectral changes associated with membrane lipids; these differences were much less pronounced between CLB-resistant and CLB-sensitive CLL cells. We demonstrate here for the first time that infrared spectroscopy can be used as a new tool for predicting ex vivo drug response (sensitivity/resistance).
Collapse
Affiliation(s)
- K Z Liu
- Institute for Biodiagnostics, National Research Council Canada, Winnipeg, Manitoba
| | | | | | | | | |
Collapse
|
10
|
Montserrat E, Bosch F, Rozman C. B-cell chronic lymphocytic leukemia: Recent progress in biology, diagnosis, and therapy. Ann Oncol 1997. [DOI: 10.1093/annonc/8.suppl_1.s93] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Schultz CP, Liu K, Johnston JB, Mantsch HH. Study of chronic lymphocytic leukemia cells by FT-IR spectroscopy and cluster analysis. Leuk Res 1996; 20:649-55. [PMID: 8913318 DOI: 10.1016/0145-2126(96)00019-7] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The peripheral mononuclear cells from 23 normal individuals and the purified B cells from 38 patients with chronic lymphocytic leukemia (CLL) were examined by Fourier transform infrared (FT-IR) spectroscopy. Differences were observed between the CLL and normal cells at the DNA, protein and lipid levels, with CLL cells having greater DNA and lower lipid contents than normal cells. In addition, the spectral character of the CLL and normal cells varied, demonstrating that there were also qualitative differences in the DNA and lipids. Statistical analysis, based on hierarchical clustering, separated normal from CLL cells completely and classified them into two subgroups for normal cells, while the CLL cells could be divided into three subgroups that were distinct from the normal cells. These differences were based on the lipid and DNA content and the overall spectral character of the cells.
Collapse
Affiliation(s)
- C P Schultz
- Institute for Biodiagnostics, National Research Council Canada, Winnipeg, Manitoba
| | | | | | | |
Collapse
|
12
|
Kay NE. Clinical utility of molecular probes in lymphoproliferative disorders. Blood Rev 1996; 10:81-8. [PMID: 8813339 DOI: 10.1016/s0268-960x(96)90036-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The use of molecular probes to diagnose and evaluate human malignancies has been most prominent in the disease category of malignant lymphoma. While this technology is daunting, it has gained rapid entry into the laboratories of both academic and community hospitals. This is because the molecular analysis of genetic changes in human disease, especially the human lymphomas, contributes to many facets of care including aiding the diagnosis, providing prognosis and helping to monitor the disease process. This review aims to highlight both the current routinely available technology and its practical applications in human lymphoma.
Collapse
Affiliation(s)
- N E Kay
- University of Kentucky Medical Center, Lexington 40536-0093, USA
| |
Collapse
|